Question Bank › Selling into a customer's own emergency

Selling into a customer's own emergency

Calls Tested
496
Answered YES
12
Hit Rate
2.4%
rare by design

Biogen Inc. (BIIB) — this company's answers

NO on the Q2 2017 call 2017-07-25 B
The model's full reasoning — Q2 2017 call → NO我们根据提供的电话会议记录,判断管理层是否描述了公司销售的产品被购买是为了缓解客户当前正面临的紧迫、代价高昂的问题。分析如下: - 管理层讨论了SPINRAZA用于脊髓性肌萎缩症(SMA),这是一种严重疾病,患者有未满足的医疗需求。他们提到患者和家属非常积极,要求治疗,并且有未满足的需求。然而,他们描述的是患者患有疾病并需要治疗,这可以被视为一种紧迫的医疗问题。但管理层是否明确将其描述为“客户正在经历的紧迫、代价高昂的问题”,并且购买是作为缓解?他们提到“未满足的医疗需求”、“患者和家属非常积极”,以及“患者要求治疗”。这暗示了紧迫性,但更多是医疗需求而非财务或运营上的紧急情况。此外,他们提到“脊柱手术”等挑战,但那是关于给药困难,而非客户的问题。 - 对于MS业务,他们提到市场竞争和患者增长,但未描述客户面临的具体紧迫问题。 - 对于biosimilars,他们提到节省成本,但那是价值主张,而非紧迫问题。 - 对于aducanumab,他们提到阿尔茨海默病,但那是未来潜力,而非当前紧迫问题。 - 管理层提到“价值导向合同”,但那是关于定价,而非客户紧迫问题。 总体而言,管理层描述的是产品满足医疗需求,但未明确描述客户正面临的具体、当前的紧迫问题(如短缺、罚款、合规等)。他们提到患者需求,但那是疾病本身,而非购买决策中的紧迫性。因此,答案应为NO。

← Back to the full BIIB analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management describe that what the company sells is being bought to relieve a PRESSING, COSTLY PROBLEM THE CUSTOMER IS ALREADY LIVING WITH RIGHT NOW — a shortage, failure, deadline, penalty, safety or compliance exposure, staffing gap, outage, backlog, spoilage, loss, or other pain the customer is actively bleeding from — such that the purchase functions as relief from an active problem rather than as an improvement, upgrade, or investment the customer could comfortably postpone? Answer YES when management's own words convey, in whatever form fits the business, ONE coherent situation: the company's offering sits on the relief side of somebody else's live emergency, and buyers are acting accordingly today. Any genuine expression of this counts, and the form varies widely across industries. For example — management describing customers who cannot get something they need and are turning to this company to fill the gap; customers facing a deadline, mandate, court order, regulatory finding, audit, or contractual penalty that this company's product or service resolves; customers whose own operations are failing, breaking down, running short, running late, or losing money every day the problem persists, and who are buying to stop the loss; customers who cannot hire, cannot deliver, cannot produce, cannot comply, or cannot serve their own customers without what this company provides; buyers whose alternative to purchasing is an outcome plainly worse and more expensive than the price being charged; or management explaining that the spending decision is being made under duress rather than out of choice, and pointing to how that shows up in real orders, urgency, willingness to pay, or the kinds of conversations they are having now. Two things should come through in management's own voice. First, the customer's pain must be CONCRETE AND CURRENTLY ACTIVE — something the buyer is dealing with today, described specifically enough that one can see what goes wrong for the customer if nothing is bought — not a general claim that the product delivers value, saves money, or improves efficiency. Second, management must present this dynamic as ALREADY VISIBLE IN THE BUSINESS NOW — in orders, demand, urgency, pricing, or customer behavior in the recent period — rather than as a reason the market should eventually be large. Answer NO if the offering is described mainly in terms of benefits, savings, productivity, better performance, or attractive returns for the customer, however compelling — that is discretionary value, not relief from an active problem. NO if the pain described belongs to the company itself rather than to its customers. NO if the customer problem is generic or abstract ("customers face cost pressure," "the industry needs to modernize," "digital transformation is a priority"). NO if the urgency is only anticipated, forecast, or expected to emerge from some future rule, cycle, or condition not yet in force. NO if the buying pressure is attributed to a brief disruption management expects to pass and is not treating as characteristic of its market. NO if the only evidence is one isolated customer anecdote with no sense of a broader pattern. NO if management merely asserts that its product is essential, mission-critical, or non-discretionary without describing what the customer is actually up against. NO if the idea appears only in an analyst's question or characterization that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
SCPH scPharmaceuticals Inc. Q3 2023 2023-11-08 B
PRPH ProPhase Labs, Inc. Q1 2023 2023-05-11 F
CEIX CONSOL Energy Inc. Q4 2022 2023-02-07 B
CRL Charles River Laboratories International Q2 2022 2022-08-03 C
SYM Symbotic Inc. Q3 2022 2022-08-01 B+
CCRN Cross Country Healthcare, Inc. Q1 2022 2022-05-04 B
GFS GLOBALFOUNDRIES Inc. Q3 2021 2021-11-30 A
TENB Tenable Holdings, Inc. Q2 2021 2021-07-27 A
MITK Mitek Systems, Inc. Q4 2017 2017-11-07 C+
DHX DHI Group, Inc. Q2 2017 2017-07-28 D
IONS Ionis Pharmaceuticals, Inc. Q1 2017 2017-05-09 C
VRNS Varonis Systems, Inc. Q2 2016 2016-08-09 B+

How the model reasoned

CEIX · Q4 2022 → YESThe question is whether management describes that what the company sells is being bought to relieve a PRESSING, COSTLY PROBLEM THE CUSTOMER IS ALREADY LIVING WITH RIGHT NOW. YES The transcript shows management describing customers buying coal to relieve an active shortage problem they are already facing. Key points include persistent coal supply shortages driving pricing, customers with low inventories (less than 20 days heading into winter), and spot needs in the back-half of the year. They also note Europe potentially relying on LNG after Russian gas depletes, and the supply of high-Btu coals still being constrained with demand remaining strong. This is presented as current market conditions visible in recent sales, pricing, and contracted volumes, not just a future improvement.
TENB · Q2 2021 → YESThe question is whether management describes that what the company sells is being bought to relieve a PRESSING, COSTLY PROBLEM THE CUSTOMER IS ALREADY LIVING WITH RIGHT NOW. YES Management describes customers facing active, ongoing cyber threats, ransomware attacks, high-profile breaches (e.g., Colonial Pipeline, Microsoft), and resulting business outages or disruptions that are driving immediate adoption of Tenable's solutions for continuous visibility, risk assessment, and prevention. This is framed as a current, pressing issue elevating discussions at the Board level and prompting purchases now, rather than future or optional improvements.
MITK · Q4 2017 → YESThe question is whether management describes that what the company sells is being bought to relieve a PRESSING, COSTLY PROBLEM THE CUSTOMER IS ALREADY LIVING WITH RIGHT NOW. YES Management describes the Equifax breach (earlier this year) as actively accelerating a "rapidly growing global problem" of verifying identity in a remote digital world, with enterprises turning to Mitek to "augment or replace traditional verification methods" because the Social Security number is "now widely breached" and "has run its race," making traditional methods "unsafe" and leading to fraud/identity theft.

More from the question bank

Analysts still asking about the old story whCenter of attention has moved to the newest Stale terms, scheduled resetLeaning into the stormManagement is playing referee between competTrajectory bent upward recently, and managemAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.